• Inogen Q1 2026 earnings call drew President, CEO and Director Kevin R.M. Smith, CFO Jason A. Richardson, SVP Investor Relations and Strategy Lorna Williams, B. Riley analyst Anderson Schock, Needham analyst Mike Matson.
• Revenue rose 3.4% to USD 85.1 million, helped by 18% international growth to USD 37.7 million; US sales fell 5% to USD 34.7 million as channel mix shifted toward portable oxygen concentrators, while unit volumes rose 14%.
• Adjusted gross margin edged up to 44.7%; adjusted EBITDA was negative USD 1.4 million as spending rose on clinical evidence and commercial investment, with management expecting Q2 and Q3 to be strongest quarters for profitability.
• Guidance was reaffirmed at USD 366 million to USD 373 million for 2026 revenue; Q2 revenue outlook set at USD 94 million to USD 97 million, with second-half scaling expected from Aurora CPAP masks and Voxi 5.
• Management cited high reorder rates for Aurora following US launch; Simeox reimbursement study IMPACTS-200 began enrolling patients; Rove 6 launched in Brazil without sizing Brazil market, positioning as premium brand in an existing tanks and POC market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inogen Inc. published the original content used to generate this news brief on May 15, 2026, and is solely responsible for the information contained therein.